IL296081A - Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo - Google Patents

Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Info

Publication number
IL296081A
IL296081A IL296081A IL29608122A IL296081A IL 296081 A IL296081 A IL 296081A IL 296081 A IL296081 A IL 296081A IL 29608122 A IL29608122 A IL 29608122A IL 296081 A IL296081 A IL 296081A
Authority
IL
Israel
Prior art keywords
conjugate
dynamicpdf
atomic group
active
pharmaceutically acceptable
Prior art date
Application number
IL296081A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of IL296081A publication Critical patent/IL296081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
IL296081A 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo IL296081A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (1)

Publication Number Publication Date
IL296081A true IL296081A (en) 2022-11-01

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296081A IL296081A (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Country Status (11)

Country Link
US (1) US20230173113A1 (https=)
EP (1) EP4117736A1 (https=)
JP (1) JP7787083B2 (https=)
KR (1) KR20220152322A (https=)
CN (1) CN115297893B (https=)
AU (1) AU2021233176A1 (https=)
BR (1) BR112022016986A2 (https=)
CA (1) CA3175061A1 (https=)
IL (1) IL296081A (https=)
MX (1) MX2022011287A (https=)
WO (1) WO2021180969A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
WO2025218677A1 (zh) * 2024-04-16 2025-10-23 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
SI3350222T1 (sl) 2015-09-18 2022-01-31 Technische Universitaet Muenchen Ligandi za integrin avbeta6, sinteza in uporaba le-teh
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
CA3090196A1 (en) 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
JP2023518161A (ja) 2023-04-28
CA3175061A1 (en) 2021-09-16
MX2022011287A (es) 2022-12-08
CN115297893B (zh) 2025-09-23
JP7787083B2 (ja) 2025-12-16
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
CN115297893A (zh) 2022-11-04
EP4117736A1 (en) 2023-01-18
BR112022016986A2 (pt) 2022-10-25
AU2021233176A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
JP7515023B2 (ja) 二重標的化化合物及びその調製方法と応用
ES3011272T3 (en) Dual mode radiotracer and -therapeutics
ES2615805T3 (es) Conjugados de antagonista de péptido análogo de la bombesina
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
AU2022219525B2 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
CA2224153C (en) Radiolabeled peptide compositions for site-specific targeting
BR112015012530B1 (pt) Compostos ligantes de receptor da neurotensina, composição e kit que os compreendem
BR112015006453B1 (pt) Antagonista de grpr radiomarcado e composição terapêutica que o compreende
IL296081A (en) Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo
JPH09506870A (ja) 金属キレート化剤
CA3118743A1 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
Maecke Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology
KR20250065913A (ko) Rgd 이량체 화합물 및 이의 제조 방법과 응용
JP2004524323A (ja) 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート
CA3119793A1 (en) Radiopharmaceuticals and methods of use thereof
AU2019338221B2 (en) CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity
US7481993B2 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
CA3224462A1 (en) Ligand compounds comprising a chelating group as a bridging group
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
KR20220104703A (ko) 영상화 및 치료용 피브린-결합 화합물
KR101551232B1 (ko) Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
EP1700608A1 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
CA3256871A1 (en) SSTR2 AGONISTS LABELED BY A RADIOISOTOPE WITH BINDERS